# Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

> **NCT04203927** · EARLY_PHASE1 · UNKNOWN · sponsor: **University of Virginia** · enrollment: 50 (estimated)

## Conditions studied

- Type2 Diabetes
- Insulin Sensitivity

## Interventions

- **DRUG:** Empagliflozin 25 MG

## Key facts

- **NCT ID:** NCT04203927
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-01
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04203927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04203927, "Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04203927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*